Titan Pharmaceuticals Inc is a development stage company developing proprietary therapeutics with utilizing ProNeura long-term, continuous drug delivery technology... Show more
Expect a price pull-back in the near future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where TTNP declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
TTNP broke above its upper Bollinger Band on September 30, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Momentum Indicator moved above the 0 level on September 30, 2025. You may want to consider a long position or call options on TTNP as a result. In of 104 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for TTNP just turned positive on September 30, 2025. Looking at past instances where TTNP's MACD turned positive, the stock continued to rise in of 49 cases over the following month. The odds of a continued upward trend are .
TTNP moved above its 50-day moving average on September 30, 2025 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for TTNP crossed bullishly above the 50-day moving average on October 03, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .
Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where TTNP advanced for three days, in of 205 cases, the price rose further within the following month. The odds of a continued upward trend are .
a developer of proprietary therapeutics for the treatment of serious medical disorders
Industry Biotechnology